Country: United States
Language: English
Source: NLM (National Library of Medicine)
MEDROXYPROGESTERONE ACETATE (UNII: C2QI4IOI2G) (MEDROXYPROGESTERONE - UNII:HSU1C9YRES)
NuCare Pharmaceuticals,Inc.
MEDROXYPROGESTERONE ACETATE
MEDROXYPROGESTERONE ACETATE 150 mg in 1 mL
INTRAMUSCULAR
PRESCRIPTION DRUG
Medroxyprogesterone Acetate Injectable Suspension is indicated only for the prevention of pregnancy. The loss of bone mineral density (BMD) in women of all ages and the impact on peak bone mass in adolescents should be considered, along with the decrease in BMD that occurs during pregnancy and/or lactation, in the risk/benefit assessment for women who use Medroxyprogesterone Acetate Injectable Suspension long-term [ see Warnings and Precautions ( 5.1) ]. The use of medroxyprogesterone acetate injectable suspension is contraindicated in the following conditions: - Known or suspected pregnancy or as a diagnostic test for pregnancy. - Active thrombophlebitis, or current or past history of thromboembolic disorders, or cerebral vascular disease [ see Warnings and Precautions ( 5.2) ]. - Known or suspected malignancy of breast [ see Warnings and Precautions ( 5.3) ]. - Known hypersensitivity to medroxyprogesterone acetate injectable suspension or any of its other ingredients [ see Warnings and Precautions ( 5.5)
NDC 68071-1818-5 BOX OF 1 Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].
Abbreviated New Drug Application
MEDROXYPROGESTERONE ACETATE- MEDROXYPROGESTERONE ACETATE INJECTION, SUSPENSION NUCARE PHARMACEUTICALS,INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE MEDROXYPROGESTERONE ACETATE INJECTABLE SUSPENSION SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR MEDROXYPROGESTERONE ACETATE INJECTABLE SUSPENSION. MEDROXYPROGESTERONE ACETATE INJECTABLE SUSPENSION, FOR INTRAMUSCULAR USE INITIAL U.S. APPROVAL: 1959 WARNING: LOSS OF BONE MINERAL DENSITY _SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._ WOMEN WHO USE MEDROXYPROGESTERONE ACETATE INJECTABLE SUSPENSION MAY LOSE SIGNIFICANT BONE MINERAL DENSITY. BONE LOSS IS GREATER WITH INCREASING DURATION OF USE AND MAY NOT BE COMPLETELY REVERSIBLE. ( 5.1) IT IS UNKNOWN IF USE OF MEDROXYPROGESTERONE ACETATE INJECTABLE SUSPENSION DURING ADOLESCENCE OR EARLY ADULTHOOD, A CRITICAL PERIOD OF BONE ACCRETION, WILL REDUCE PEAK BONE MASS AND INCREASE THE RISK FOR OSTEOPOROTIC FRACTURE IN LATER LIFE. ( 5.1) MEDROXYPROGESTERONE ACETATE INJECTABLE SUSPENSION SHOULD NOT BE USED AS A LONG-TERM BIRTH CONTROL METHOD (I.E., LONGER THAN 2 YEARS) UNLESS OTHER BIRTH CONTROL METHODS ARE CONSIDERED INADEQUATE. ( 5.1) RECENT MAJOR CHANGES 1. Dosage and Administration, Prevention of Pregnancy ( 2.1) 11/2016 Warnings and Precautions, Injection Site Reactions ( 5.6) 11/2016 INDICATIONS AND USAGE Medroxyprogesterone Acetate Injectable Suspension is a progestin indicated only for the prevention of pregnancy. ( 1) DOSAGE AND ADMINISTRATION The recommended dose is 150 mg of medroxyprogesterone acetate injectable suspension every 3 months (13 weeks) administered by deep, intramuscular (IM) injection in the gluteal or deltoid muscle. ( 2.1) DOSAGE FORMS AND STRENGTHS Vials containing sterile aqueous suspension: 150 mg per mL ( 3) CONTRAINDICATIONS Known or suspected pregnancy or as a diagnostic test for pregnancy. ( 4) Active thrombophlebitis, or current or past history of thromboembolic disorders, or cerebral vascular Read the complete document